UPC CoA 446/2025

Vor dem UPC: BOEHRINGER INGELHEIM INTERNATIONAL GMBH (3 Verfahren)·Zentiva Group (15 Verfahren)

• 2025-08-13
  Appeal RoP220.1Öffentlich

  Zusammenfassung: The Court of Appeal set aside the Lisbon Local Division's refusal to grant provisional measures and ordered a preliminary injunction against Zentiva Portugal prohibiting the making, offering, placing on the market or use of nintedanib products (Nintedanib Zentiva 100mg and 150mg soft capsules) for idiopathic pulmonary fibrosis in 17 UPC Contracting Member States while EP 1 830 843 remains in force. The court held that completion of national HTA/pricing/reimbursement procedures constitutes imminent infringement. Zentiva was ordered to pay EUR 199,000 as an interim award of costs. The request for an information order was denied.

  Rechtsfragen anzeigen (5)

  • Imminent infringement in generic medicines context
  • Marketing authorisation vs HTA/pricing procedures as imminent infringement
  • Order to communicate information under Art. 67 UPCA
  • National law as source of law under Art. 24 UPCA
  • Provisional measures in pharmaceutical patent disputes